Company: SNSE
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0000950170-25-053033
Chunk: 50

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 50
---
 non-revocation of a separation agreement, including a release of claims, and compliance with certain restrictive covenants. Policy on Hedging and Speculative Trading Our insider trading and window period policy prohibits directors, officers and employees from engaging in short sales, transactions in put or call options, hedging transactions, margin accounts or other inherently speculative transactions with respect to our stock at any time.

<div align='center'>30</div>

Insider Trading Policy

We have adopted an Insider Trading Policy governing the purchase, sale, and/or other dispositions of our securities by directors, officers, employees and consultants that is designed to promote compliance with insider trading laws, rules and regulations, as well as procedures designed to further the foregoing purposes. A copy of our insider trading policy was filed as Exhibit 19.1 to our Annual Report on Form 10-K for our fiscal year ended December 31, 2024.

From time to time, we may also engage in transactions in our own securities, such as in connection with our ongoing stock repurchase program. We have procedures in place designed to ensure our compliance with applicable laws and regulations relating to insider trading in connection with any such transactions.

Clawback Policy

In October 2023, the Compensation Committee adopted our Incentive Compensation Recoupment Policy (the “Clawback Policy”), designed to comply with Rule 10D-1 of the Exchange Act and Nasdaq Listing Rule 5608, which provides for recoupment of incentive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the relevant securities laws. The Clawback Policy applies to our current and former executive officers. Compensation that is granted, earned or vested based wholly or in part upon attainment of a Financial Reporting Measure (as defined in the Clawback Policy) is subject to recoupment.

<div align='center'>31</div>

Outstanding Equity Awards as of December 31, 2024 The following table sets forth certain information about equity awards granted to our named executive officers that remained outstanding as of December 31, 2024:

| Name                        |     | Grant Date |     | Option Awards 
 Number of     
 Securities    
 Underlying    
 Unexercised   
 Options       
 Exercisable   |         |     | Number of     
 Securities    
 Underlying    
 Unexercised   
 Options       
 Unexercisable |         |     |    |     | Option   
 Exercise 
 Price    |        |     | Option     
 Expiration 
 Date       |